Want to see KYTX full AI Analyst Report?
Kyverna Therapeutics, Inc. (KYTX) AI Stock Analysis
Kyverna Therapeutics, Inc.
(NASDAQ:KYTX)
The score is primarily weighed down by weak financial performance (zero revenue, widening losses, and heavy negative operating/free cash flow) and bearish technicals (price below major moving averages with negative MACD). Offsetting these risks, a notable positive corporate event—durable, favorable clinical data with a planned rolling BLA submission targeted for Q4 2026—provides meaningful upside potential, but does not fully counter near-term burn and trend weakness.
Kyverna Therapeutics, Inc. (KYTX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $301.80M
- Dividend Yield
- ―
- Average Volume (3M)
- 860.01K
- Price to Earnings (P/E)
- -1.7
- Beta (1Y)
- 1.90
- Revenue Growth
- ―
- EPS Growth
- 20.07%
- Country
- US
- Employees
- 149
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Kyverna Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatme...
How the Company Makes Money
Kyverna Therapeutics does not have product revenue from commercialized therapies (null). Its cash inflows have primarily come from financing activities typical of clinical-stage biotech companies, including proceeds from equity financings such as its...
Kyverna Therapeutics, Inc. Earnings Call Summary
The earnings call revealed significant advancements in Chimera's immunology pipeline, particularly with the initiation of KT61 and advancement of KT474. However, the deprioritization of the oncology program and extended timelines for KT474 indicate strategic shifts that could pose challenges. The financial stability and focus on promising immunology assets contribute to an overall positive outlook.
Q3-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Chimera Therapeutics Q3 2024 earnings call, significant guidance was provided, highlighting several key metrics and strategic directions. The company has initiated a Phase 1 study of KT61, an oral STAT6 degrader, with expectations to complete the Healthy Volunteer Study in the first half of 2025. The program aims to address diseases with TH2 inflammation, affecting over 150 million patients across the US, Europe, and Japan. Additionally, Chimera has advanced its KT474 program, transitioning it to expanded Phase 2B studies, supported by partner Sanofi, and is preparing KT295, a new lead candidate in their TIC2 program, for Phase 1 trials in 2025. Financially, Chimera raised approximately $600 million in 2024, boasting a cash runway into mid-2027, and reported $3.7 million in revenue for the quarter, attributed to their Sanofi collaboration. The company is strategically reallocating resources to prioritize their growing immunology pipeline, with plans to share further guidance on clinical developments next year.
Kyverna Therapeutics, Inc. Financial Statement Overview
Summary
Overall financial profile is weak for now: the income statement reflects zero TTM revenue and materially widening losses (TTM net loss about -$152.6M; EBIT about -$158.9M), while cash flow shows heavy ongoing burn (TTM operating cash flow about -$158.8M; TTM free cash flow about -$159.4M). The balance sheet is a relative offset with low-to-moderate leverage (debt-to-equity ~0.20 TTM), but equity has declined meaningfully (to ~$165.5M TTM), indicating continued erosion from losses.
Income Statement
18Very NegativeBalance Sheet
56NeutralCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 7.03M | 5.66M |
| Gross Profit | -351.00K | 0 | -2.13M | -1.71M | 7.03M | 5.66M |
| EBITDA | -149.28M | -159.02M | -125.20M | -58.47M | -27.78M | -25.76M |
| Net Income | -152.64M | -161.31M | -127.48M | -60.37M | -28.89M | -26.35M |
Balance Sheet | ||||||
| Total Assets | 219.82M | 293.83M | 304.64M | 75.19M | 66.92M | 85.49M |
| Cash, Cash Equivalents and Short-Term Investments | 199.43M | 279.25M | 285.98M | 57.54M | 51.32M | 76.07M |
| Total Debt | 33.00M | 29.03M | 8.24M | 9.08M | 10.56M | 5.55M |
| Total Liabilities | 54.27M | 61.55M | 38.06M | 26.02M | 140.92M | 131.74M |
| Stockholders Equity | 165.55M | 232.28M | 266.59M | 49.18M | -74.00M | -46.25M |
Cash Flow | ||||||
| Free Cash Flow | -159.43M | -153.72M | -116.45M | -53.03M | -36.88M | -23.44M |
| Operating Cash Flow | -158.75M | -153.71M | -114.25M | -52.41M | -36.11M | -22.16M |
| Investing Cash Flow | -8.80M | 40.02M | -160.90M | -8.79M | -14.10M | -1.29M |
| Financing Cash Flow | 145.92M | 141.17M | 337.11M | 58.12M | 11.88M | 72.52M |
Kyverna Therapeutics, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYTX, the sentiment is Negative. The current price of 4.88 is below the 20-day moving average (MA) of 5.57, below the 50-day MA of 6.55, and below the 200-day MA of 7.98, indicating a bearish trend. The MACD of -0.43 indicates Positive momentum. The RSI at 34.16 is Neutral, neither overbought nor oversold. The STOCH value of 14.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KYTX.
Kyverna Therapeutics, Inc. Risk Analysis
Kyverna Therapeutics, Inc. disclosed 86 risk factors in its most recent earnings report. Kyverna Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksKyverna Therapeutics, Inc. Peers Comparison
Overall Rating
AVIR62Neutral
SLN55Neutral
HRTX46Neutral
TRDA44Neutral- KYTX44Neutral
CDXS43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AVIR | 62Neutral | $345.68M | -2.07 | -64.25% | ― | ― | -29.71% |
| SLN | 55Neutral | $1.23B | -5.18 | -106.94% | ― | ― | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HRTX | 46Neutral | $55.63M | -1.56 | -300.90% | ― | 0.99% | -3014.75% |
| TRDA | 44Neutral | $191.45M | -1.27 | -64.00% | ― | -93.54% | -53.55% |
| KYTX | 44Neutral | $301.80M | -1.66 | -81.91% | ― | ― | 20.07% |
| CDXS | 43Neutral | $118.27M | -3.21 | -74.36% | ― | 35.89% | 58.70% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KYTX | Kyverna Therapeutics, Inc. | 4.88 | -1.51 | -23.63% | |
| CDXS | Codexis | 1.08 | -0.67 | -38.29% | |
| HRTX | Heron Therapeutics Inc | 0.29 | -0.82 | -73.60% | |
| SLN | Silence Therapeutics Plc | 19.73 | 13.38 | 210.71% | |
| AVIR | Atea Pharmaceuticals, Inc. | 4.31 | 0.98 | 29.43% | |
| TRDA | Entrada Therapeutics Inc | 4.89 | -2.37 | -32.64% |
Kyverna Therapeutics, Inc. Corporate Events
Kyverna Reports Positive One-Year Data for Miv-Cel
PositiveOn September 24, 2026, Kyverna Therapeutics reported positive one-year topline data from its KYSA-8 registrational trial of miv-cel in stiff person syndrome, showing sustained improvements in mobility, disability, and stiffness, with 92% of patients...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026